Long term study confirms efficacy of ISA Pharmaceuticals' T-cell activating immunotherapy in combination with checkpoint inhibitor

OEGSTGEEST, Netherlands, March 1, 2022 /PRNewswire/ -- ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, today announces the publication of extension data from a key study using lead product ISA101b in the...